Key regions: Australia, Japan, United States, Germany, Europe
The Anti-Coagulants market in Kuwait has been steadily growing in recent years.
Customer preferences: Patients in Kuwait suffering from cardiovascular diseases and other conditions that require blood thinners have been increasingly opting for Anti-Coagulants as a treatment option. This is due to the fact that Anti-Coagulants have proven to be more effective and safer than traditional blood thinners like Warfarin. Additionally, the convenience of once-daily dosing and fewer dietary restrictions have also contributed to the popularity of Anti-Coagulants.
Trends in the market: The Anti-Coagulants market in Kuwait is expected to continue growing due to the increasing prevalence of cardiovascular diseases and a growing elderly population. The market is also expected to see a shift towards newer oral Anti-Coagulants, such as Apixaban and Rivaroxaban, which have shown to have better safety profiles and fewer side effects compared to traditional blood thinners. Additionally, the market is expected to see increased competition as more pharmaceutical companies enter the market with their own Anti-Coagulant products.
Local special circumstances: Kuwait has a high prevalence of cardiovascular diseases, which has contributed to the growth of the Anti-Coagulants market. Additionally, the country has a high-income population with a strong healthcare infrastructure, which has made it easier for patients to access and afford Anti-Coagulant treatments.
Underlying macroeconomic factors: The Kuwaiti government has been investing heavily in the healthcare sector, which has contributed to the growth of the Anti-Coagulants market. Additionally, the country has a stable economy and a high GDP per capita, which has made it easier for patients to afford Anti-Coagulant treatments. However, the market may face challenges in the future due to increasing healthcare costs and potential regulatory changes.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
